A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2015
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CORIN
- 31 Aug 2018 Biomarkers information updated
- 21 Jan 2015 Planned End Date changed from 1 Oct 2021 to 1 Jan 2020 as reported by ClinicalTrials.gov record.
- 21 Jan 2015 Planned primary completion date changed from 1 Oct 2021 to 1 Jan 2020 as reported by ClinicalTrials.gov record.